compounds were resolved. The substituents used in the 1-position were chosen from a principal component analysis (PCA) plot constructed from both tabulated variables and variables calculated by semiempirical methods (PM3) and molecular mechanics software (MMX). Among the analogs prepared, some, e.g., compound 21, were equipotent to compound 5 with respect to 5-HT1A effects. All compounds were more or
一系列针对5-(1-丙基
氨基)-6,7,8,9-四
氢-3H-
苯并[e]
吲哚-1-
甲醛的有效5-HT1A的1-,3-和4-取代基(5 )制备并在5-HT1A,5-HT1Dα,5-HT1Dβ,D2和D3受体上进行体外测试,并在
利血平预处理的大鼠中进行
5-HTP和
DOPA积累测定中的激动剂活性体内测试。一些化合物已解决。从主成分分析(
PCA)图中选择在1位使用的取代基,该图由列表变量和通过半经验方法(
PM3)和分子力学软件(M
MX)计算的变量构成。在制备的类似物中,一些例如化合物21就5-HT1A作用而言与化合物5等价。所有化合物都对5-HT1A受体具有选择性,